Arakere G, Frasch C E
Division of Bacterial Products, Food and Drug Administration, Bethesda, Maryland 20892.
Infect Immun. 1991 Dec;59(12):4349-56. doi: 10.1128/iai.59.12.4349-4356.1991.
Most group C Neisseria meningitidis strains produce an O-acetyl-positive polysaccharide, a homopolymer of alpha-2----9-linked N-acetylneuraminic acid with O-acetyl groups at the C-7 and C-8 of its sialic acid residues. The majority of disease isolates have been reported to contain this polysaccharide. Some strains produce group C polysaccharide lacking O-acetyl groups. The licensed vaccine contains the O-acetyl-positive polysaccharide. We have measured the antibody specificities to the two polysaccharides in sera from asymptomatic group C meningococcal carriers and vaccinated adults by a new enzyme-linked immunosorbent assay (ELISA) procedure using methylated human serum albumin for coating the group C polysaccharide onto microtiter plates. Inhibition of binding of serum antibodies to polysaccharide-coated plates was measured by ELISA after incubation with O-acetyl-positive and O-acetyl-negative group C polysaccharides. Greater inhibition of binding of carrier sera was observed with the homologous polysaccharide. There was substantial inhibition of binding of vaccinee sera to the O-acetyl-positive polysaccharide-coated plate following preincubation with O-acetyl-positive polysaccharide, but homologous inhibition on plates coated with the O-acetyl-negative polysaccharide required much higher concentrations of polysaccharide. Carrier sera may have a higher proportion of antibodies with greater specificity for the O-acetyl-negative polysaccharide, while vaccinee sera contain antibodies with greater affinity for the O-acetyl-positive polysaccharide. Studies with monoclonal antibodies specific for O-acetyl-positive and O-acetyl-negative polysaccharides reveal that the percentage of group C meningococcal disease caused by O-acetyl-negative strains remains about 15%, as found over 15 years ago.
大多数C群脑膜炎奈瑟菌菌株产生一种O - 乙酰化阳性多糖,它是α-2----9连接的N - 乙酰神经氨酸的同聚物,其唾液酸残基的C - 7和C - 8位带有O - 乙酰基。据报道,大多数疾病分离株都含有这种多糖。一些菌株产生缺乏O - 乙酰基的C群多糖。已获许可的疫苗含有O - 乙酰化阳性多糖。我们通过一种新的酶联免疫吸附测定(ELISA)程序,使用甲基化人血清白蛋白将C群多糖包被在微量滴定板上,来检测无症状C群脑膜炎球菌携带者和接种疫苗的成年人血清中针对这两种多糖的抗体特异性。在用O - 乙酰化阳性和O - 乙酰化阴性C群多糖孵育后,通过ELISA测定血清抗体与多糖包被板结合的抑制情况。观察到同源多糖对携带者血清结合的抑制作用更强。在用O - 乙酰化阳性多糖预孵育后,接种疫苗者血清与O - 乙酰化阳性多糖包被板的结合受到显著抑制,但在O - 乙酰化阴性多糖包被板上的同源抑制则需要更高浓度的多糖。携带者血清中可能含有更高比例的对O - 乙酰化阴性多糖具有更高特异性的抗体,而接种疫苗者血清中含有对O - 乙酰化阳性多糖具有更高亲和力的抗体。对O - 乙酰化阳性和O - 乙酰化阴性多糖特异性单克隆抗体的研究表明,由O - 乙酰化阴性菌株引起的C群脑膜炎球菌疾病的百分比仍保持在约15%,与15年前的情况相同。